Our approach is to allow different phenotypes to be visualized and quantified simultaneously in the same tissue section, enabling researchers to study the relationships and distribution of these cells within tumors and within the tumor micro-environment.
Using standard FFPE (Formalin-fixed, Paraffin-embedded) biopsies.
CD3, CD4, CD8, CD11b, CD11c, CD14, CD15, CD16, CD20, CD31, CD33, CD39, CD44, CD45, CD45RO, CD56, CD57, CD66b, CD66c, CD68, CD69, CD73, CD103, CD115, CD133, CD137, CD155, CD163, CD195, CD206, CD326, AFP, ALDH1/2, Alpha SMA, Bax, Bcl2, BDNF, Beta-actin, CA9, CCR7, cGAS, CK, CSF1R, CXCL10, CXCR5, DOG1, E-cadherin, EGLN1, Estrogen receptor alpha, FGB(fibrinogen), Fibrin, FOXP3, Glut1, Granzyme B, HePTP, Her2, HLA Class I, HLA Class II, IDO, IL15, IL17A, Ki67, LAG3, LRRC15, MAGEA1, Mannose receptor, M-CST, MPO, N-cadherin, NDRG1, NELFA, Oct4, Pan-keratin, PD-1, PD-L1, Phospho-AKT, Phospho-Stat1, Phospho-Stat3, Phospho-Smad2, Phospho-Smad3, PSMB10, PVR, ROR gamma T, SLAMF6, Snail, SOX2, SOX10, SP-B, T-bet, TBR2, TCF1, TCF8, TERT, TGF-bata, TGF-beta1, TGFBI(BIGH3), TIGHT, TIM3, TrkB, Vimentin, WT1, Xct, and etc.
Inquiry for other antibody settings
CD3, CD4, CD8, CD11b, CD11c, CD19, CD20, CD25, CD31, CD45, CD56, CD68, CD73, CD80, CD86, CD161c, CD163, CD206, AFP, Active caspase3, alpha-SMA, Arginase2, cGAS, CXCL9, CXCL10, E2F8, EGFP, FAM20c, FOXP3, GIP, GLP1, GPC3, Gr1 (Ly6G+Ly6C), Granzyme B, IBA1, IFN-gamma, IL-1beta, IL-6, Ki67, Ly6G, LYVE1, MAGE1, MCP1, PD-1, PD-L1, PDPN, Xcr1, and etc.
Inquiry for other antibody settings